Sponsor study identifier
Secondary identifiers
EUDRACT_NUMBER
OTHER · The Regional Research Ethics Committees Denmark
NIH
interventional
218
1 country
2
Study Start
May 1, 2018
Actual (reported)Primary Completion
December 31, 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
A person who has experienced a cardiac arrest with no apparent cause is at risk of having recurrent cardiac arrest. Hence an implantable cardioverter-defibrillator (ICD) is recommended on empirical grounds. Today, there is no uniform way of approaching prevention of recurrence in idiopathic ventricular fibrillation (IVF) patients, beside ICD implantation. Better reatment and risk stratification tools are needed Medical treatment in these patients has never been assessed systematically, but at least some patients with no apparent diagnosis are on betablocker treatment. It is not known if low-doselow dose betablocker treatment is beneficial in these patients. This study investigates the effect of betablocker treatment to reduce arrhythmic burden in IVF patients. No predictors for appropriate ICD therapy have been identified in patients with IVF. It is also explored if toxicological and/or genetic profiles, together with in depth machine learning simulation data on repolarization patterns from IVF-ECGs compared to controls, can be used as risk stratification tools. Lastly, QOL in IVF patients and the impact of beta blocker treatment will be investigated.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 1, 2018
Actual (reported)January 26, 2026
Actual (reported)February 12, 2026
Actual (reported)December 31, 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
First appropriate therapy by ICD or 3 years after discharge
Primary outcome will be either first appropriate therapy by ICD (anti tachycardia pacing or DC conversion), or aborted shock or non-sustained ventricualr fibrillation detected by the ICD, where the treating physician opts for a change in medication, or no therapy from the ICD 3 years after randomization, whichever comes first.
3 years
Quality of Life at 3 months
3 months
Quality of Life at 1 year
1 year
Standard care
The betablocker given to the patient will be prioritized: 1) A non-selective betablocker: Propranolol Retard 80 mg daily or Nadolol 40 mg daily OR 2) A selective betablocker: Atenolol 25 mg daily, Bisoprolol 2.5 mg daily or Metoprolol 50 mg.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The Heart Center, Rigshospitalet
Copenhagen, Dr., 2100, Denmark
Odense University Hospital
Odense, 5000, Denmark
Bo G Winkel, MD
The Heart Center, Rigshospitalet
First Submitted
January 26, 2026
First Posted
February 12, 2026
Study Start
May 1, 2018
Actual (reported)Primary Completion
December 31, 2032
EstimatedCangrelor in Comatose Survivors of OHCA Undergoing Primary PCI
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 1, 2026
Record last verified: 2026-02
GDPR
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: